Deal News

  • 10 July 2019

    BioNTech secures $325m in series B funding

    German company BioNTech has raised $325m in a series B financing round to support further development of its therapeutics pipeline and manufacturing infrastructure.

  • 9 July 2019

    Addex to lead mGlu7 NAM-focused PTSD consortium

    Swiss-headquartered Addex Therapeutics has announced it will lead a consortium to develop small molecule negative allosteric modulators (NAMs) indicated to reduce fear memory in post-traumatic stress disorder (PTSD).


Go Top